A Phase 2 interventional study of BAY73-4506 (Regorafenib, Stivarga) in Solid Cancer, sponsored by Bayer. Completed at 6 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 54th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2019, is one of 29 in phase 2, and was the 36th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–75
National Cancer Institute, Naples · Sites in Italy
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 39 · Phase 3 9 · Phase 4 3
First in 2009; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 58 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
32 studies in Colorectal Neoplasms by Bayer: 2 open now, 2 under way, none of them phase 3. Of 29 finished, 6 (21%) have results posted.
Among the 32 studies in Colorectal Neoplasms by Bayer, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2019, is one of 7 in phase 2, and was the 22nd registered.
Bayer’s Colorectal Neoplasms studies by the year they started, since 2008.
3 of the studies testing regorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06558773Chinese PLA General HospitalGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | 2027-03-01 |
| NCT06425133Centre Hospitalier Universitaire de BesanconRegorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers | 2027-09 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 32 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.
The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to continue regorafenib treatment after their respective study has been completed, and b) to further assess the safety of regorafenib. Secondary objective is the documentation of drug tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
Drug: BAY73-4506 (Regorafenib, Stivarga)
Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
Also known as: Tyrosine-kinase inhibitor
Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: 1. results in death 2. is life-threatening 3. requires inpatient hospitalization or prolongation of existing hospitalization, etc.
Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Severity (by Worst Grade) of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Number and Severity of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug.
Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug. AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Number of Participants With Dose Modifications
Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
The study was conducted in multiple centers located in 5 countries (including Germany, Japan, Italy, United Kingdom, United States), first subject first visit of the study was on 02 APR 2019 and last subject last visit was on 28 FEB 2023.
| Milestone | Regorafenib |
|---|---|
| Started | 6 |
| Completed | 0 |
| Not completed | 6 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Patient's decision | 1 |
| Withdrew: Adverse event | 4 |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: 1. results in death 2. is life-threatening 3. requires inpatient hospitalization or prolongation of existing hospitalization, etc.
| participants | Regorafenib |
|---|---|
| Any AE | 6 |
| - Non-serious | 6 |
| - Serious | 3 |
AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
| participants | Regorafenib |
|---|---|
| Worst grade - Grade 1 | 0 |
| Worst grade - Grade 2 | 2 |
| Worst grade - Grade 3 | 1 |
| Worst grade - Grade 4 | 3 |
| Worst grade - Grade 5 (death) | 0 |
A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug.
| participants | Regorafenib |
|---|---|
| Any AE | 5 |
| - Non-serious | 5 |
| - Serious | 1 |
A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug. AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
| participants | Regorafenib |
|---|---|
| Worst grade - Grade 1 | 1 |
| Worst grade - Grade 2 | 3 |
| Worst grade - Grade 3 | 0 |
| Worst grade - Grade 4 | 1 |
| Worst grade - Grade 5 (death) | 0 |
| participants | Regorafenib |
|---|---|
| Any modification | 6 |
| Interruption/Delay | 2 |
| Drug withdrawn | 5 |
Collected over from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Event | Regorafenib |
|---|---|
| PeritonitisInfections and infestations | 1/6 |
| Electrocardiogram changeInvestigations | 1/6 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/6 |
| HyponatraemiaMetabolism and nutrition disorders | 1/6 |
| Renal failureRenal and urinary disorders | 1/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 |
| Event | Regorafenib |
|---|---|
| ConstipationGastrointestinal disorders | 2/6 |
| HypokalaemiaMetabolism and nutrition disorders | 2/6 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 2/6 |
| HypertensionVascular disorders | 2/6 |
| AnaemiaBlood and lymphatic system disorders | 1/6 |
| Retinal vein occlusionEye disorders | 1/6 |
| Abdominal painGastrointestinal disorders | 1/6 |
| Abdominal pain upperGastrointestinal disorders | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 |
| NauseaGastrointestinal disorders | 1/6 |
| Age, Continuous(years) | Regorafenib |
|---|---|
| Median | 61 (44 to 71) |
| Sex: Female, Male(Participants) | Regorafenib |
|---|---|
| Female | 3 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Regorafenib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Regorafenib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Apr 2019 to primary completion in Feb 2023, 46 months.
Results were first posted in Apr 2024, 1 year 1 month after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 46 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib